You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九芝堂(000989.SZ):REMD-477項目在美國已完成1型糖尿病的Ⅱ期臨牀試驗
格隆匯 05-23 19:20

格隆匯5月23日丨九芝堂(000989.SZ)於2023年5月23日15:00-17:00召開業績説明會,交流環節中,就“科信美德REMD477項目幾年前就説要三期了,到現在也沒有消息,是不是效果不好,取消,今後這項目就不繼續下去;REMD-477項目進展?九芝堂投資的科信美德糖尿病藥物研發三期臨牀進展如何?”,公司回覆稱,REMD-477項目在美國已經完成了1型糖尿病的Ⅱ期臨牀試驗,公司參股公司北京科信美德與其母公司REMD Biotherapeutics Inc在2021年美國糖尿病協會(ADA)第81屆科學會議(ADA2021)上首次發佈研發新藥Volagidemab (即REMD-477項目)治療1型糖尿病患者的Ⅱ期臨牀試驗結果。目前暫無重大進展,如有最新進展,公司將在接到相關通知後根據規定進行公吿。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account